Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.

@article{Suh2006PhaseIS,
  title={Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.},
  author={John H. Suh and Baldassarre Stea and Abdenour Nabid and John J Kresl and Andr{\'e} Fortin and Jean-Philippe Mercier and Neil N. Senzer and Eric L. Chang and Adam P Boyd and Pablo J. Cagnoni and Edward Shaw},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 1},
  pages={106-14}
}
PURPOSE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain metastases when used as an adjunct to whole-brain radiation therapy (WBRT). PATIENTS AND METHODS Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either efaproxiral at 75 or 100 mg/kg (efaproxiral arm) or no efaproxiral (control arm). The primary end point was… CONTINUE READING